The age‑old debate: hire a contract research organization (CRO) or keep it in‑house? In Europe, big pharma often mixes both. CROs like IQVIA and Parexel bring global reach and niche expertise — from rare disease recruitment to complex biomarker analysis. The Europe clinical trials market research study shows that pharmaceutical companies hold the largest end‑use share, but biotechnology firms are the fastest‑growing.

But in‑house teams offer tighter control and institutional knowledge. For pivotal Phase III trials, many companies prefer a hybrid model: CRO for site management and monitoring, internal team for strategy and oversight. The Europe clinical trials market trends highlight that patient recruitment services are the most outsourced function, as CROs have pre‑existing relationships with investigators.

Cost is another factor. Eastern Europe (Poland, Hungary, Czech Republic) offers lower costs per patient while maintaining high data quality standards. Western Europe (Germany, France, UK) offers speed and regulatory expertise but at a premium.

Ultimately, the best approach depends on your drug, timeline, and budget. But one thing is clear: CROs are no longer just vendors — they're strategic partners.